Category Archives: Stem Cells

PUBLIC RELEASE DATE:

5-Jun-2014

Contact: Jenna Brown jbrown66@partners.org 617-855-2110 McLean Hospital

BELMONT, MA -- Researchers at Harvard-affiliated McLean Hospital have found that fetal dopamine cells transplanted into the brains of patients with Parkinson's disease were able to remain healthy and functional for up to 14 years, a finding that could lead to new and better therapies for the illness.

The discovery, reported in the June 5, 2014 issue of the journal Cell Reports, could pave the way for researchers to begin transplanting dopamine neurons taken from stem cells grown in laboratories, a way to get treatments to many more patients in an easier fashion.

"We have shown in this paper that the transplanted cells connect and live well and do all the required functions of nerve cells for a very long time," said Ole Isacson, MD (DR MED SCI), director of the Neuroregeneration Research Institute at McLean and a professor of neurology and neuroscience at Harvard Medical School.

The researchers looked at the brains of five patients who got fetal cell transplants over a period of 14 years and found that their dopamine transporters (DAT), proteins that pump the neurotransmitter dopamine, and mitochondria, the power plants of cells, were still healthy at the time the patients died, in each case of causes other than Parkinson's.

The fact that these cells had remained healthy indicated that the transplants had been successful and that the transplanted cells had not been corrupted as some researchers had suggested they likely had been in other studies, said Dr. Isacson, lead author of the paper.

"These findings are critically important for the rational development of stem cell-based dopamine neuronal replacement therapies for Parkinson's," the paper concluded.

So far, about 25 patients worldwide have been treated with this particular method of transplanting fetal dopamine cells over a period of two decades and most saw their symptoms improve markedly, he said.

Follow this link:
McLean Hospital researchers see promise in transplanted fetal stem cells for Parkinson's

The great promise of stem cells may finally be getting close for multiple sclerosis patients.

Stem cells, which have the power to transform into other types of cells, have been much anticipated for more than a decade as a way to treat or even cure diseases like MS, Parkinson's, blindness and spinal cord injuries. But it's taken time to turn that promise into a workable reality.

Two new studies, both published in the journal Stem Cell Reports, suggest that researchers are getting close.

"We haven't landed on the moon yet, but we've tested the rockets," said Jeanne Loring, author of one of the studies and a professor and director of the Center for Regenerative Medicine at The Scripps Research Institute in La Jolla, Calif.

Her study found that a certain type of stem cell, injected once into the spinal cords of mice with an MS-like condition, could dramatically improve the animals for at least six months.

The mice's immune systems almost immediately rejected and destroyed the cells, known as human embryonic stem cell-derived neural precursor cells. But the cells seemed to trigger a long-lasting benefit, dampening inflammation to slow the disease's progression, and repairing the damaged sheathing around nerve cells that is the hallmark of MS, according to Thomas Lane, a neural immunologist at the University of Utah who helped lead the research.

The other study, led by Robert Lanza, chief scientific officer of Advanced Cell Technology, a Massachusetts-based biotech, showed that mice with an MS-like disease could be restored to near normal by injecting them with a different type of stem cell. When injected, these cells ?? mesenchymal stem cells derived from human embryonic stem cells ?? were able to home in on damaged cells in the nervous system, even crossing the blood-brain barrier, Lanza said.

They not only reduced the symptoms of the disease, but prevented more damage to nerve cells, he said.

The two studies together "speak to the changing role of stem cells and their potential as treatment strategies for MS," said Tim Coetzee with the National Multiple Sclerosis Society, an advocacy group. The idea of using stem cells in MS has been around for a while, but these two studies overcome some of the challenges of finding a therapy that can be consistent and effective for many people.

"They set the stage quite impressively for potential work in humans," he said, with clinical trials likely within the next few years.

Link:
New stem cells may help in battling multiple sclerosis

PUBLIC RELEASE DATE:

5-Jun-2014

Contact: Robert Miranda cogcomm@aol.com Cell Transplantation Center of Excellence for Aging and Brain Repair

Putnam Valley, NY. (June 5, 2014) A study by a Korean team of neuroscientists has concluded that when mesenchymal stem cells (MSCs; multipotent structural stem cells capable of differentiation into a variety of cell types) are transplanted into the brains of mice modeled with Alzheimer's disease (AD), the cells stimulate neural cell growth and repair in the hippocampus, a key brain area damaged by AD. The finding could lead to improved AD therapies.

The study will be published in a future issue of Cell Transplantation and is currently freely available on-line as an unedited early e-pub at: http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-CT1059Oh.

Neuroscientists know that Alzheimer's disease is caused by the presence of amyloid-B (AB) "plaques" and "tangles" in the brain's network of neurons. Recently, a protein signaling pathway called "Wnt" (Wingless-type mouse mammary tumor virus (MMTV) related integration site family) which plays a role in embryonic development as well as the development of some diseases, such as cancer, has been linked to Alzheimer's disease. Researchers speculate that an interruption in the Wnt pathway signaling process caused by the AB plaque buildup may have an impact on potential brain cell renewal processes, called neurogenesis. Evidence has indicated that the Wnt signaling pathway plays an important role in the pathogenesis of AD.

This study was carried out to determine if MSCs benefitted neurogenesis in the hippocampus by "modulating" the Wnt pathway in such a way that that the MSCs are able to differentiate into neuronal progenitor cells (NPCs) that could help rebuild the affected areas of the brain.

"Recent studies have shown that MSCs express various proteins related to the Wnt pathway," said study co-author Dr. Phil Hyu Lee, Department of Neurology, Yonsei University College of Medicine in Seoul, South Korea. "It has also been determined that MSCs derived from bone marrow produce biologically active Wnt proteins that may counteract the negative influence of AB on neuronic activity."

The authors report that MSC treatment of AD in cellular and animal models significantly increased hippocampal neurogenesis and enhanced neuronal differentiation of NPCs.

"Our data suggest that the modulation of adult neurogenesis and neuronal differentiation to repair the damaged AD brain using MSCs could have a significant impact on future strategies for AD treatment," the researchers concluded.

View post:
Stem cells found to play restorative role when affecting brain signaling process

PUBLIC RELEASE DATE:

3-Jun-2014

Contact: Sandra Hutchinson s3.hutchinson@qut.edu.au 61-731-389-449 Queensland University of Technology

A QUT scientist is hoping to unlock the potential of stem cells as a way of repairing neural damage to the brain.

Rachel Okolicsanyi, from the Genomics Research Centre at QUT's Institute of Health and Biomedical Innovation, said unlike other cells in the body which were able to divide and replicate, once most types of brain cells died, the damage was deemed irreversible.

Ms Okolicsanyi is manipulating adult stem cells from bone marrow to produce a population of cells that can be used to treat brain damage.

"My research is a step in proving that stem cells taken from the bone marrow can be manipulated into neural cells, or precursor cells that have the potential to replace, repair or treat brain damage," she said.

Ms Okolicsanyi's research has been published in Developmental Biology journal, and outlines the potential stem cells have for brain damage repair.

"What I am looking at is whether or not stem cells from the bone marrow have the potential to differentiate or mature into neural cells," she said.

"Neural cells are those cells from the brain that make everything from the structure of the brain itself, to all the connections that make movement, voice, hearing and sight possible."

Follow this link:
Unlocking the potential of stem cells to repair brain damage

Reports of a new kind of stem cell, produced by simply stressing mature mouse cells, kicked up a storm of controversy soon after their publication in Nature on 30 January. Duplicated and manipulated images as well as plagiarism were found in the two papers, which led to a verdict of misconduct for the lead author, Haruko Obokata of the RIKEN Center for Developmental Biology in Kobe, Japan. There have also been calls for a retraction (which, for at least one of the papers, looks increasingly likely). But the controversy has left open a key question: does the phenomenon,known as stimulus-triggered acquisition of pluripotency, or STAP,exist?

The answer, according to Japanese media reports today on the results of genetic tests on the cells used in the STAP experiments, is no.

STAP cells were claimed to be made by exposing bodily cells to acid or subjecting them to physical pressure. These cells take on characteristics of embryonic stem cells. If further manipulated, they will also form self-renewing stem cell lines, called STAP stem cells, which share most properties of the embryonic stem cell lines. The Nature papers reported the creation of eight STAP stem cell lines. (Note: Natures news and comment team is editorially independent of its research editorial team.)

In March, one of the co-authors of the STAP papers, Teruhiko Wakayama of Yamanashi University, did a simple genetic analysis and found that some of the supposed STAP stem cell lines he had produced outside of the experiments described in the papers did not match the strain of mouse from which they were supposed to have been derived. This would mean that the cells came from a different mouse to that claimed, suggesting contamination. But he did not find a problem with the STAP stem cell lines that were reported in the Nature papers. To verify his results, Wakayama sent some 20 stem cell lines, including samples of the eight reported in the papers, to an independent, but unnamed, genetic analysis team for more precise tests.

According to Japanese media reports quoting multiple sources, the results of those tests have now been sent to RIKEN, Obokatas employer and the institution that found her guilty of misconduct. They conclude that none of the STAP stem cell lines match the original mouse strains from which they were supposedly taken, calling into question whether the STAP phenomenon has ever been demonstrated.Wakayama says he will release detailed results at a press conference soon.

It was also reported that RIKEN will likely enlist Obokata in its ongoing efforts to try to reproduce the STAP results.

More:
Genetic tests suggest STAP stem cells never existed

GOLTRY, Okla. Armed with stem cells, a Goltry area woman will be heading to Milwaukee next week to join in her brothers cancer fight.

Jeni Sumner was the only match among family members tested to donate stem cells to her younger brother, Ed Dee.

To me, Ive been given a gift. I know everybodys congratulating me and saying its a wonderful thing, and not taking it away from that, but I think Ive been given just a tremendous gift, Sumner said.

Along with helping her brother, Sumner is trying to encourage others to join the bone marrow donor registry.

I think a lot of people are afraid to join because they might get called, because they dont know what its like to be a donor, she said. I want more people to become aware of what its actually like to be a donor.

Sumner set up a Facebook page It Doesnt Hurt - To Save a Life to chronicle everything she will go through, as a donor, during the procedure.

Its an unknown for me, but its nothing compared to what my brothers going through, she said. I know the feeling that I got when I got the call from the doctor saying that I was his donor. The relief and the joy that I felt that our family doesnt have to look anymore. If anything happens, were covered because we have a donor, we have a match. The feeling that I got was incredible, she said.

Dee, of Milwaukee, Wis., was diagnosed with acute myelogenous leukemia last year. Sumner said he went into remission last October.

Unfortunately, the cancer came back. This type of leukemia is a very dangerous and aggressive form. He, every couple of weeks, would go in for a blood test and this March he was informed that his leukemia had come back, she said. His doctors feel that a stem cell transplant would be the best for him, at this time.

Following the return of the cancer, Dee went through five days of rigorous chemotherapy to put him back into remission. He recently finished a lower dose session of chemo, Sumner said.

Read more from the original source:
Using stem cells, woman joins brothers cancer fight

Posted on behalf of David Cyranoski

The retraction of two controversial papers which promised a simple way to create embryonic-like stem cells appears imminent today after the lead author unexpectedly gave her full consent. Haruko Obokata, of the RIKEN Center for Developmental Biology in Kobe, Japan, had been the last obstacle to the retraction of both papers.

She agreed to retract the second of the two studies last week, but her agreement yesterday to retract the first one, which detailed the fundamental mechanism behind her claims, paves the way for the unravelling of what was heralded as one of the biggest scientific discoveries of the year.

All co-authors of the papers, which claimed to have created a new type of stem cell, known as stimulus-triggered activation of pluripotency (STAP) cells, now appear to have consented to the retraction. This leaves the papers fate in the hands of Nature, the journal that published the two studies in January. Requests for retractions with the unanimous support of the co-authors are usually authorised by the publisher. (Note: Natures news and comment team is editorially independent of its research editorial team.)

In the STAP studies, Obokata claimed that when she stressed cells by exposing them to acid or putting pressure on their membranes, they underwent a transformation to an embryonic-like cell. The STAP cells therefore shared the ability of embryonic stem cells and induced pluripotent stem (iPS) cells to convert into any of the bodys cell types, promising a huge advance to biomedical research and clinical applications.

But Obokatas papers quickly came under fire after various manipulated and duplicated images were found in them. After an investigation into the allegations, RIKEN found Obokata guilty of misconduct on 1 April. Earlier this month, it rejected her appeal of the judgment, and asked her to retract both papers. In the meantime, at least a dozen other research groups reported that they were unable to replicate her findings.

As the controversy escalated, several co-authors publicly stated their desire for a retraction. But Obokata and a senior co-author on the papers, Charles Vacanti, of the Brigham and Womens Hospital in Boston, Massachusetts, stood by the papers.

However, in an unexpected move on 28 May, Obokata consented to the retraction of the second paper, which describes how STAP cells can form placental cells as well as embryonic-like and iPS cells. But she remained resolutely behind the main paper, considering the second just an extension, her lawyer Hideo Miki said.

Then, out of the blue on 30 May, Vacanti sent a letter to Nature asking for a retraction of the first paper. This move may have broken Obokatas resistance. On 3 June she signed an agreement to retract the first paper and handed it to RIKEN, a spokesperson confirmed. The spokesperson says that the authors are now in discussion with Nature with regard to retraction of both papers. Nature does not discuss retractions until final decisions are made.

See the original post here:
Last remaining support for controversial stem-cell papers collapses

"It's a tiny wee finger prick test," says senior nurse Patsy Scouse to calm the nervous first-time donor having his hemoglobin levels tested at a blood donation centre in Edinburgh.

The Scottish National Blood Transfusion Service receives donations from about four percent of the UK's population. Currently, stocks are stable, although the service is always trying to recruit new donors.

The collection may take place in a clinical environment, the nurse says, but the clinic "wants this experience, especially for first-time donors, to be really positive so they can go out and feel they've done a really good thing."

But the service is also working on potential new technologies to secure blood supplies in the future, including "artificial blood."

Mass-produced and clean

Mark Turner, medical director of the Blood Transfusion Service, is looking into how blood could be synthesized in the future.

"We've known for some time that it's possible to produce red blood cells from so called adult stem cells, but you can't produce large amounts of blood in that way because of the restrictive capacity of those cells to proliferate," he explains. What scientists can do, he adds, is to derive pluripotent stem cells - stem cell lines - either from embryos or from adult tissue.

These cells are processed in the laboratory to produce larger numbers of cells, Turner told DW.

"It may be possible in due course to manufacture blood on a very large scale, but we're a very long way from that at the present time," he says. "At the moment, our focus is on trying to achieve production of red blood cells which are of the right kind of quality and safety, that they would be fit for human trials."

From the lab to clinical trials

The rest is here:
Artificial blood made from human stem cells could plug the donations hole

A Littlestown resident went through a five-day procedure to give bone marrow stem cells to a man living in France

By Adam Michael

amichael@GameTimePA.com

@goodoletwonames on Twitter

John Sibirtzeff will never meet the man who used his stem cells to heal. He'll never know exactly what his affliction was, and he's OK with that.

A month ago, Sibirtzeff spent five days in Washington D.C. donating bone marrow stem cells that would be used to heal a 69-year-old man living in France.

"I'll never know who the recipient was," he said. "I'll never know if he was American or French, military or non."

When Sibirtzeff, of Littlestown, was in Navy boot camp in 2007, he opted into the C.W. Bill Young Department of Defense Marrow Donor Program. Naval doctors drew a vial of his blood and stored it after identifying his type. In 2011, Sibirtzeff finished his tour of duty, but his name remained on the donor list.

This past January, the program contacted Sibirtzeff requesting that he return for testing, as he was a potential match for a 69-year-old man living in France.

According to the program's website, salutetolife.org, 70 percent of patients are unable to find a match within their families. Sibirtzeff's receiver was among them.

Read the original:
Everyday Hero: Littlestown man donates bone marrow stem cells to stranger

Durham, NC - Duke researchers have found a new type of neuron in the adult brain that is capable of telling stem cells to make more new neurons. Though the experiments are in their early stages, the finding opens the tantalizing possibility that the brain may be able to repair itself from within.

Neuroscientists have suspected for some time that the brain has some capacity to direct the manufacturing of new neurons, but it was difficult to determine where these instructions are coming from, explains Chay Kuo, M.D. Ph.D., an assistant professor of cell biology, neurobiology and pediatrics.

In a study with mice, his team found a previously unknown population of neurons within the subventricular zone (SVZ) neurogenic niche of the adult brain, adjacent to the striatum. These neurons expressed the choline acetyltransferase (ChAT) enzyme, which is required to make the neurotransmitter acetylcholine. With optogenetic tools that allowed the team to tune the firing frequency of these ChAT+ neurons up and down with laser light, they were able to see clear changes in neural stem cell proliferation in the brain.

The findings appeared as an advance online publication June 1 in the journal Nature Neuroscience.

The mature ChAT+ neuron population is just one part of an undescribed neural circuit that apparently talks to stem cells and tells them to increase new neuron production, Kuo said. Researchers don't know all the parts of the circuit yet, nor the code it's using, but by controlling ChAT+ neurons' signals Kuo and his Duke colleagues have established that these neurons are necessary and sufficient to control the production of new neurons from the SVZ niche.

"We have been working to determine how neurogenesis is sustained in the adult brain. It is very unexpected and exciting to uncover this hidden gateway, a neural circuit that can directly instruct the stem cells to make more immature neurons," said Kuo, who is also the George W. Brumley, Jr. M.D. assistant professor of developmental biology and a member of the Duke Institute for Brain Sciences. "It has been this fascinating treasure hunt that appeared to dead-end on multiple occasions!"

Kuo said this project was initiated more than five years ago when lead author Patricia Paez-Gonzalez, a postdoctoral fellow, came across neuronal processes contacting neural stem cells while studying how the SVZ niche was assembled.

The young neurons produced by these signals were destined for the olfactory bulb in rodents, as the mouse has a large amount of its brain devoted to process the sense of smell and needs these new neurons to support learning. But in humans, with a much less impressive olfactory bulb, Kuo said it's possible new neurons are produced for other brain regions. One such region may be the striatum, which mediates motor and cognitive controls between the cortex and the complex basal ganglia.

"The brain gives up prime real estate around the lateral ventricles for the SVZ niche housing these stem cells," Kuo said. "Is it some kind of factory taking orders?" Postdoctoral fellow Brent Asrican made a key observation that orders from the novel ChAT+ neurons were heard clearly by SVZ stem cells.

Studies of stroke injury in rodents have noted SVZ cells apparently migrating into the neighboring striatum. And just last month in the journal Cell, a Swedish team observed newly made control neurons called interneurons in the human striatum for the first time. They reported that interestingly in Huntington's disease patients, this area seems to lack the newborn interneurons.

The rest is here:
Neuron Tells Stem Cells to Grow New Neurons